Biorestorative Therapies, INC

Biorestorative Therapies announces significant executive departures and board appointments, alongside amendments to executive employment agreements.

BioRestorative Therapies, Inc. has entered into a new three-year employment agreement with its Vice President of Research and Development, Francisco Silva.

BioRestorative Therapies, Inc. entered into a $1 million revolving loan agreement with Bowery Group LLC, resulting in the resignation of three directors and the appointment of three lender-designated board members.

BioRestorative Therapies stockholders approved an increase in authorized common stock to 1.5 billion shares and formalized executive employment agreements.

BioRestorative Therapies has finalized discretionary cash bonuses and total compensation packages for its top executive leadership team for the 2025 fiscal year.

BioRestorative Therapies, Inc. has published an updated corporate presentation for use in upcoming investor meetings and conferences.

BioRestorative Therapies, Inc. reported a narrowed net loss for Q1 2026, improved working capital, and a strengthened cash position, though it faces Nasdaq minimum bid price non-compliance.

BioRestorative Therapies, Inc. reported a significant increase in net loss and cash burn for Q3 and the nine months ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern.

BioRestorative Therapies, Inc. reported increased revenue driven by new product sales but continued significant net losses and a going concern warning, alongside identified material weaknesses in internal controls.

BioRestorative Therapies' Q1 2025 results reveal a widened net loss due to increased research and development expenses, despite a slight decrease in revenue.

BioRestorative Therapies reported its third quarter 2024 results, showing increased revenue and providing updates on its financial position and clinical programs.

BioRestorative Therapies reports a net loss of $6.3 million for the first half of 2024, but also highlights $7.5 million in net proceeds from a warrant exercise program.

BioRestorative Therapies reported a significant net loss and negative cash flow for 2025, raising substantial doubt about its ability to continue as a going concern, despite clinical progress and recent capital raises.

BioRestorative Therapies files its 10-K, highlighting clinical trial progress, financial results, and future plans in cell therapy.

BioRestorative Therapies, Inc. filed an amendment to its annual report to include a description of its securities and anti-takeover provisions.

BioRestorative Therapies restated its past financial statements due to a misapplication of accounting guidance related to warrants, leading to the identification of a material weakness in internal controls.

BioRestorative Therapies has granted stock options to an executive and a board member as part of their compensation packages.

BioRestorative Therapies' VP of R&D, Francisco Silva, acquired common stock and warrants, increasing his beneficial ownership.

BioRestorative Therapies' President, CEO, and COB, Lance Alstodt, acquired 15,625 common shares and 11,719 warrants.

David A. Rosa, a director of BioRestorative Therapies, Inc., reports the acquisition of stock options exercisable for 52,632 shares of common stock.

Patrick F. Williams, a director at BioRestorative Therapies, Inc., acquired stock options for 52,632 shares of common stock on February 14, 2025.

Director Nickolay V. Kukekov reports acquisition of stock options in BioRestorative Therapies, Inc.

Robert Eugene Kristal, CFO of BioRestorative Therapies, Inc., reports acquisition of stock options.

BioRestorative Therapies is holding a special meeting on May 26, 2026, to vote on increasing authorized common stock from 75 million to 1.5 billion shares, aiming to fund clinical trials and general corporate needs.

BioRestorative Therapies, Inc. announces its Annual Meeting to address director elections, a stock incentive plan increase, auditor ratification, and executive compensation amidst ongoing net losses and declining shareholder returns.

BioRestorative Therapies is holding its annual meeting on September 19, 2024, to vote on the election of a director, an amendment to the stock incentive plan, and the ratification of its independent auditor.

BioRestorative Therapies, Inc. filed an S-1/A amendment to include a Placement Agency Agreement and a revised filing fee table for its proposed public offering of securities.

BioRestorative Therapies is offering up to 9.7 million units, aiming to raise $10 million to fund clinical trials and R&D, amidst ongoing substantial losses and going concern doubts.

BioRestorative Therapies filed a resale S-1 registering 508,592 shares underlying October 2025 warrants, with no proceeds to the company unless warrants are exercised at $2.75.

BioRestorative Therapies, Inc. files an amendment to its Form S-1 registration statement to include additional exhibits related to its corporate structure, agreements, and legal opinions.

BioRestorative Therapies has filed a registration statement for the potential resale of up to 2,513,686 shares of its common stock by existing securityholders.

BioRestorative Therapies, Inc. has granted a substantial stock option to its Vice President of Research and Development, Francisco Silva, increasing his beneficial ownership to approximately 15.1% of the company's common stock.

BioRestorative Therapies, Inc. has granted its CEO, Lance Alstodt, a ten-year option to purchase 791,885 shares of common stock at an exercise price of $2.46 per share, significantly increasing his beneficial ownership to 15.5%.

Alta Partners LLC has filed a Schedule 13G, reporting beneficial ownership of 4.99% of BioRestorative Therapies, Inc. common stock.

Auctus Fund, LLC and its affiliates have reported a 9.9% beneficial ownership stake in BioRestorative Therapies, Inc. through common stock and warrant holdings.

Todd Hale Morrison has filed an Amendment No. 8 to Schedule 13G, reporting zero beneficial ownership in BioRestorative Therapies, Inc. as of February 23, 2026.

Auctus Fund, LLC and its affiliates reported a 9.9% beneficial ownership stake in BioRestorative Therapies, Inc., totaling 895,896 shares.

Alta Partners LLC has disclosed a 7.7% beneficial ownership stake in BioRestorative Therapies, Inc., holding 1,787,163 shares of common stock.

Todd Hale Morrison has increased his beneficial ownership in BioRestorative Therapies, Inc. to 7.7% of common stock.